Product nameAnti-Asporin antibody
See all Asporin primary antibodies
DescriptionGoat polyclonal to Asporin
Tested applicationsSuitable for: WB, IHC-P, ICC/IF, ELISAmore details
Species reactivityReacts with: Mouse, Human
Predicted to work with: Rat
- Human bone marrow lysate.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferpH: 7.30
Preservative: 0.02% Sodium azide
Constituents: Tris buffered saline, 0.5% BSA
Concentration information loading...
PurityImmunogen affinity purified
Purification notesPurified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide
Our Abpromise guarantee covers the use of ab31303 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 1 - 3 µg/ml. Detects a band of approximately 40 kDa (predicted molecular weight: 43 kDa).|
|IHC-P||Use at an assay dependent dilution. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. PubMed: 20541802|
|ICC/IF||Use at an assay dependent dilution.|
|ELISA||Use at an assay dependent concentration.|
FunctionNegatively regulates periodontal ligament (PDL) differentiation and mineralization to ensure that the PDL is not ossified and to maintain homeostasis of the tooth-supporting system. Inhibits BMP2-induced cytodifferentiation of PDL cells by preventing its binding to BMPR1B/BMP type-1B receptor, resulting in inhibition of BMP-dependent activation of SMAD proteins (By similarity). Critical regulator of TGF-beta in articular cartilage and plays an essential role in cartilage homeostasis and osteoarthritis (OA) pathogenesis. Negatively regulates chondrogenesis in the articular cartilage by blocking the TGF-beta/receptor interaction on the cell surface and inhibiting the canonical TGF-beta/Smad signal. Binds calcium and plays a role in osteoblast-driven collagen biomineralization activity.
Tissue specificityHigher levels in osteoarthritic articular cartilage, aorta, uterus. Moderate expression in small intestine, heart, liver, bladder, ovary, stomach, and in the adrenal, thyroid, and mammary glands. Low expression in trachea, bone marrow, and lung. Co-localizes with TGFB1 in chondrocytes within osteoarthritic (OA) lesions of articular cartilage.
Involvement in diseaseGenetic variations in ASPN are associated with susceptibility to osteoarthritis type 3 (OS3) [MIM:607850]; also known as osteoarthritis of knee/hip. Osteoarthritis is a degenerative disease of the joints characterized by degradation of the hyaline articular cartilage and remodeling of the subchondral bone with sclerosis. Clinical symptoms include pain and joint stiffness often leading to significant disability and joint replacement. Note=Susceptibility to osteoarthritis is conferred by a triplet repeat expansion polymorphism. ASPN allele having 14 aspartic acid repeats in the N-terminal region of the protein (D14), is overrepresented relative to the common allele having 13 aspartic acid repeats (D13). The frequency of the D14 allele increases with disease severity. The D14 allele is also overrepresented in individuals with hip osteoarthritis.
Defects in ASPN are a cause of susceptibility to intervertebral disk disease (IDD) [MIM:603932]. A common musculo-skeletal disorder caused by degeneration of intervertebral disks of the lumbar spine. It results in low-back pain and unilateral leg pain. Note=Susceptibility to intervertebral disk disease, particularly lumbar disk degeneration, is conferred by a triplet repeat expansion polymorphism. ASPN allele having 14 aspartic acid repeats in the N-terminal region of the protein (D14), is associated with the disorder in some populations (PubMed:18304494).
Sequence similaritiesBelongs to the small leucine-rich proteoglycan (SLRP) family. SLRP class I subfamily.
Contains 11 LRR (leucine-rich) repeats.
Contains 1 LRRNT domain.
DomainThe LRR 5 repeat can inhibit BMP2-induced cytodifferentiation and may be involved in the interaction with BMP2 (By similarity). The repeats LRR 10, LRR 11 and LRR 12 are involved in binding type I collagen. The poly-Asp region is involved in binding calcium.
modificationsThere is no serine/glycine dipeptide sequence expected for the attachment of O-linked glycosaminoglycans and this is probably not a proteoglycan. The O-linked polysaccharide on 54-Ser is probably the mucin type linked to GalNAc.
The N-linked glycan at Asn-282 is composed of variable structures of GlcNAc, mannose, fucose, HexNAc and hexose.
Cellular localizationSecreted > extracellular space > extracellular matrix.
- Information by UniProt
- ASPN antibody
- ASPN protein antibody
- ASPN_HUMAN antibody
All lanes : Anti-Asporin antibody (ab31303) at 1/1000 dilution
All lanes : Human osteosarcoma cell line whole lysate
Lysates/proteins at 30 µg per lane.
All lanes : HRP-conjugated anti-goat IgG polyclonal at 1/2000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 43 kDa
Observed band size: 42 kDa why is the actual band size different from the predicted?
Exposure time: 1 minute
Blocked with 5% milk for 1 hour at 27°C.
Incubated with the primary antibody diluted in blocking buffer for 12 hours at 4°C.
Anti-Asporin antibody (ab31303) at 0.3 µg/ml + Human Bone Marrow lysate (35µg protein in RIPA buffer)
Predicted band size: 43 kDa
Observed band size: 40 kDa why is the actual band size different from the predicted?
Primary incubation was 1 hour. Detected by chemiluminescence.
ab31303 (4µg/ml) staining of paraffin embedded Human Colon. Steamed antigen retrieval with citrate buffer pH 6, HRP-staining. Shows textured staining in the cytoplasm of absorptive cells.
Ab31303 staining of ATDC5 cells (Panels A and C) and DAPI (panels B and D). Image shows staining of cytoplasm and on the cell surface. Data gratefuly received from Dr. Shiro Ikegawa, SNP Research Center, RIKEN, Japan.
This product has been referenced in:
- Maccarana M et al. Asporin-deficient mice have tougher skin and altered skin glycosaminoglycan content and structure. PLoS One 12:e0184028 (2017). Read more (PubMed: 28859141) »
- Hurng JM et al. Discontinuities in the human bone-PDL-cementum complex. Biomaterials 32:7106-17 (2011). ICC/IF ; Human . Read more (PubMed: 21774982) »